Angle-supported phakic IOLs banned in France

Article

Angle-supported phakic IOLs can no longer be sold or implanted in France because of their association with significant endothelial cell loss, which was discovered in patients two to three years after implantation.

Angle-supported phakic IOLs can no longer be sold or implanted in France because of their association with significant endothelial cell loss, which was discovered in patients two to three years after implantation.

Manufacturers, IOLTech/Carl Zeiss Meditec and Corneal have withdrawn the Vivarte and NewLife phakic IOLs and the Icare lens, respectively, in accordance with the French Agency for Sanitary Safety of Health Products (AFSSAPS) orders.

A retrospective study was organized to determine the incidence and cause and it was found that, out of 2,324 lenses implanted, 27 had to be removed because of significantly high cell loss.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.